Washington Clinical Trials Report — April 2026

For individuals in Washington considering participation in clinical research, April 2026 brings a critical window of opportunity, especially for those looking to join studies with rapidly approaching enrollment deadlines. Across the state, a significant number of trials are concluding recruitment soon, with 111 studies slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 12 of these time-sensitive trials are actively seeking participants without specific health conditions. If you've been contemplating contributing to medical advancements, now is a crucial time to explore these options before they are no longer available.

Act Now: Trials Closing Soon Across Washington

Patients managing specific health conditions also face impending deadlines to join research efforts. A variety of trials focused on mental health, chronic diseases, and oncology are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Alcohol use disorder (AUD)
• Major depressive disorder
• Stage IV lung cancer
• Heart failure
• Mild traumatic brain injury
• PTSD
• Anatomic stage II breast cancer
• Alzheimer disease
• Breast cancer
• Ulcerative colitis

These studies represent diverse areas of medical need, offering a chance to contribute to new treatments and understanding for conditions affecting many Washingtonians. We encourage interested individuals to review these opportunities promptly.

New Research Frontiers: Obesity, Cancer, and Public Health Innovations

This month, Washington welcomes 11 new clinical trials, offering fresh opportunities for participation. While this marks a slight decrease from the 15 new trials launched in March 2026, the quality and potential impact of these new studies remain high. Notably, several significant Phase 2 and 3 trials from major sponsors are opening their doors, providing access to cutting-edge research.

• Novo Nordisk A/S is sponsoring NCT07509307, a Phase 3 study titled "AMAZE 6." This research investigates the effectiveness and safety of a new medicine, NNC0487-0111, for individuals with excess body weight and knee osteoarthritis. The study aims to enroll 400 participants, evaluating a once-weekly injectable treatment compared to a placebo.
• For oncology patients, Incyte Corporation is launching NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important trial seeks 588 participants to assess new treatment strategies for a challenging cancer.
• Caliway Biopharmaceuticals Co., Ltd. is initiating NCT07526974, a Phase 3 study named "SUPREME-02." This randomized, double-blinded, placebo-controlled study will evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat, enrolling 320 participants.
• In a significant public health initiative, Seattle Children's Hospital is sponsoring NCT07522112, "Evaluating a Shared Decision-making Intervention for Families About Firearm Storage." This randomized controlled trial, designed for 548 participants, will assess the effectiveness of the Family Safety Check-In website on firearm storage practices, following a robust language adaptation process.
• The Seattle Institute for Biomedical and Clinical Research is leading NCT07507435, a study focused on "Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults." This research, involving 480 participants, addresses the elevated risk of community-acquired pneumonia in people with HIV despite effective antiretroviral therapy.
• Legacy Health System is conducting NCT07506876, a Phase 2 study on "Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer." This trial, with 30 participants, aims to determine if taking endocrine therapy concurrently with chemotherapy and HER2 directed therapy improves outcomes for hormone receptor positive, HER2 positive breast cancer.

These notable trials, alongside others, contribute to a diverse research landscape, with drug trials accounting for 6 of the new studies this month. Behavioral, biological, device, and procedure-based interventions each represent one new trial, while another study falls under the 'other' category.

Washington's Research Footprint: Where Can You Participate?

With 1,663 clinical trials currently recruiting across 69 cities and 799 research sites, Washington offers extensive opportunities for participation. This month's new trials show a clear concentration in the state's largest urban centers, with 8 of the 11 new studies opening in Seattle. Other cities welcoming new research include Bellevue, Renton, Spokane, and Vancouver, each with one new trial. While Seattle remains a hub for clinical research, the overall distribution of trials ensures accessibility across a wide geographic area of the state.

The conditions targeted by these new trials reflect a broad spectrum of health concerns, from specific cancers to metabolic disorders and infectious diseases. New opportunities include research for:

• Acute graft versus host disease
• Breast cancer - infiltrating ductal carcinoma
• Chronic graft versus host disease
• Diabetes
• Diabetes mellitus, type 1
• Diabetes mellitus, type 2
• Hematopoietic and lymphatic system neoplasm
• HER-2 positive breast cancer
• HIV

This diversity ensures that many individuals, regardless of their specific health challenges, may find a relevant study close to home.

Participation Opportunities: Healthy Volunteers and Diverse Demographics

Clinical trials in Washington are designed to be inclusive, welcoming a wide range of participants. Of the 11 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunities to contribute to medical science. Additionally, 2 new trials are open to children, and one study is specifically designed for male participants.

For individuals without a specific medical condition, there are significant avenues to contribute to research. 3 of the new trials this month are actively seeking healthy volunteers. More broadly, a total of 153 clinical trials are currently recruiting healthy participants statewide, providing numerous opportunities for those interested in supporting medical research without having a particular diagnosis.

Academic institutions and major medical centers continue to drive significant research efforts in Washington. This month, sponsors like Fred Hutchinson Cancer Center, Bloodworks, and Legacy Health System are leading new studies. Industry leaders such as Novo Nordisk A/S, Incyte Corporation, and Caliway Biopharmaceuticals Co., Ltd. are also making substantial contributions, with industry-sponsored trials accounting for 5 of the new studies this month, and other organizations sponsoring 6.

As we move through April, the focus will continue to be on enrolling participants in these innovative studies, particularly those with upcoming deadlines. The ongoing research efforts in Washington are vital for advancing medical knowledge and improving patient care across a broad spectrum of health challenges.